HK1070669A1 - Growth hormone fusion protein - Google Patents

Growth hormone fusion protein

Info

Publication number
HK1070669A1
HK1070669A1 HK05100765.8A HK05100765A HK1070669A1 HK 1070669 A1 HK1070669 A1 HK 1070669A1 HK 05100765 A HK05100765 A HK 05100765A HK 1070669 A1 HK1070669 A1 HK 1070669A1
Authority
HK
Hong Kong
Prior art keywords
growth hormone
fusion protein
hormone fusion
modified
binding domain
Prior art date
Application number
HK05100765.8A
Other languages
English (en)
Inventor
Richard Ross
Peter Artymiuk
Jon Sayers
Original Assignee
Asterion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterion Ltd filed Critical Asterion Ltd
Publication of HK1070669A1 publication Critical patent/HK1070669A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
HK05100765.8A 2001-12-14 2005-01-28 Growth hormone fusion protein HK1070669A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0130052A GB2384001B (en) 2001-12-14 2001-12-14 Chimeric growth hormone-growth hormone receptor proteins
PCT/GB2002/005523 WO2003070765A2 (en) 2001-12-14 2002-12-06 Growth hormone fusion protein

Publications (1)

Publication Number Publication Date
HK1070669A1 true HK1070669A1 (en) 2005-06-24

Family

ID=9927705

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100765.8A HK1070669A1 (en) 2001-12-14 2005-01-28 Growth hormone fusion protein

Country Status (20)

Country Link
US (2) US7524649B2 (ru)
EP (2) EP2365085A1 (ru)
JP (2) JP5248734B2 (ru)
KR (3) KR100848802B1 (ru)
CN (2) CN101638437A (ru)
AT (1) ATE541935T1 (ru)
AU (1) AU2002366325B2 (ru)
CA (1) CA2468439A1 (ru)
ES (1) ES2378424T3 (ru)
GB (2) GB2384001B (ru)
HK (1) HK1070669A1 (ru)
HU (1) HUP0402496A3 (ru)
IL (3) IL162433A0 (ru)
MX (1) MXPA04005675A (ru)
NZ (1) NZ533550A (ru)
PL (1) PL210714B1 (ru)
RU (2) RU2346047C2 (ru)
SG (1) SG160205A1 (ru)
WO (1) WO2003070765A2 (ru)
ZA (2) ZA200404488B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316944A3 (en) * 2000-06-16 2011-11-02 Asterion Limited Binding agents: chimeric ligand/receptor proteins
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
JP2008507292A (ja) * 2004-07-26 2008-03-13 アステリオン・リミテッド リンカー
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
GB0606946D0 (en) * 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
GB0618082D0 (en) * 2006-09-14 2006-10-25 Asterion Ltd Growth factor
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
GB0717985D0 (en) * 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
WO2009077731A2 (en) * 2007-12-19 2009-06-25 Asterion Limited Prolactin fusion proteins
WO2011085070A2 (en) * 2010-01-06 2011-07-14 Virginia Tech Intellectual Properties, Inc. Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
JP5412323B2 (ja) 2010-02-26 2014-02-12 日東電工株式会社 貼付製剤
GB201104285D0 (en) * 2011-03-15 2011-04-27 Asterion Ltd Modified receptor fusion proteins
EP2606908A1 (en) 2011-12-19 2013-06-26 Ipsen Pharma S.A.S. Novel pharmaceutical composition for a long acting growth hormone fusion protein (LAGH)
CA2863499C (en) * 2012-02-03 2022-06-21 George Tachas Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
CN105229035A (zh) * 2013-03-11 2016-01-06 诺和诺德保健股份有限公司 生长激素化合物
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
WO2020014307A1 (en) * 2018-07-11 2020-01-16 Ohio University Peptide-based inhibitors of growth hormone action and methods of the thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
WO1992021029A1 (en) * 1991-05-10 1992-11-26 Genentech, Inc. Selecting ligand agonists and antagonists
IT1251895B (it) * 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
US5686268A (en) * 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
WO1997011178A1 (en) 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
DE69712124T2 (de) * 1996-02-13 2002-12-12 Jcr Pharmaceutical Co Hormones de croissance humaines mutantes et leur utilisation
AU725474B2 (en) 1996-08-16 2000-10-12 Medical Research Council Self-replicating episomal expression vectors conferring tissue-specific gene expression
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL144259A0 (en) * 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
EP2316944A3 (en) * 2000-06-16 2011-11-02 Asterion Limited Binding agents: chimeric ligand/receptor proteins
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins

Also Published As

Publication number Publication date
GB2389115A (en) 2003-12-03
AU2002366325A1 (en) 2003-09-09
US20050123558A1 (en) 2005-06-09
GB2384001B (en) 2004-02-04
RU2346047C2 (ru) 2009-02-10
ZA200600149B (en) 2006-10-25
CN1604965A (zh) 2005-04-06
GB0130052D0 (en) 2002-02-06
US7524649B2 (en) 2009-04-28
JP5248734B2 (ja) 2013-07-31
ATE541935T1 (de) 2012-02-15
PL371313A1 (en) 2005-06-13
IL162433A (en) 2011-09-27
JP2010043100A (ja) 2010-02-25
GB2384001A (en) 2003-07-16
ES2378424T3 (es) 2012-04-12
GB2389115B (en) 2005-03-16
KR20070108254A (ko) 2007-11-08
HUP0402496A2 (hu) 2005-03-29
EP1456385B1 (en) 2012-01-18
EP1456385A2 (en) 2004-09-15
PL210714B1 (pl) 2012-02-29
CA2468439A1 (en) 2003-08-28
ZA200404488B (en) 2006-03-29
KR20060106862A (ko) 2006-10-12
KR20040083470A (ko) 2004-10-02
HUP0402496A3 (en) 2012-03-28
MXPA04005675A (es) 2005-04-19
CN101638437A (zh) 2010-02-03
CN100558899C (zh) 2009-11-11
AU2002366325B2 (en) 2008-04-24
SG160205A1 (en) 2010-04-29
IL162433A0 (en) 2005-11-20
EP2365085A1 (en) 2011-09-14
RU2004117777A (ru) 2005-05-10
US20090239801A1 (en) 2009-09-24
NZ533550A (en) 2006-02-24
KR100848802B1 (ko) 2008-07-28
KR100879553B1 (ko) 2009-01-22
RU2008118104A (ru) 2009-11-20
WO2003070765A2 (en) 2003-08-28
JP2005525106A (ja) 2005-08-25
IL200659A0 (en) 2010-05-17
GB0320479D0 (en) 2003-10-01
WO2003070765A3 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
HK1070669A1 (en) Growth hormone fusion protein
WO2000018932A3 (en) Receptor based antagonists and methods of making and using
IL222149B (en) A protein comprising a modified version of the fc region of a human antibody with increased binding affinity to fcrn
PL336306A1 (en) Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
HK1144684A1 (en) Igf-1 fusion polypeptides and therapeutic uses thereof igf-1
IL166750A0 (en) Modified transferrin fusion proteins
IL146451A0 (en) C-terminal protein tagging
IL158751A0 (en) Recombinant fusion proteins and the trimers thereof
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
IL166343A0 (en) Igg fc/hiv-gp 120/c3d fusion protein
AU2002250049A8 (en) Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins
PL374349A1 (en) Hcv fusion proteins with modified ns3 domains
EP1181052A4 (en) AREAS WITH INTENDED ACTIVITIES BASED ON PROTEIN A
MXPA01003868A (es) Apomixis conferida por la expresion de proteinas que interactuan con la cinasa receptora de embriogenesis somatica.
AU1077200A (en) Novel chimeric polypeptide
EP0999848A4 (en) CHIMEAN PROTEINS FOR TREATING DIABETES
AU3087599A (en) Human appetite control by glucagon-like peptide receptor binding compounds
GB9819998D0 (en) Immunoglobulin binding protein
DE69927375D1 (de) Fusionsprotein mit direkter verknüpfung des il-6-rezeptors mit il-6
GB9818124D0 (en) CD28 binding protein
EP1421114A4 (en) G-PROTEIN COUPLED RECEPTORS
AU8149001A (en) A novel polypeptide, a human TNFR/NGFR protein containing cytochrome C domain and the ploynucleotide encoding the polypeptide
GB9909578D0 (en) Immunoglobulin binding protein
AU2001293639A1 (en) A novel polypeptide-human tnfr/ngfr protein 15 that contains cytochrome c structural domain and the polynucleotide encoding said polypeptide
NZ501161A (en) Chimeric human trkA-IgG polypeptides which bind to human nerve growth factor.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151206